Sam-A Pharm. Co., Ltd
Financials
Valuation Metrics
Sam-A Pharm. Co., Ltd's Market Cap is ₩790B. At end of 2025 it was ₩1001B. Ranked #1395 of 2,436 in KR market (top 57%), #785 of 1,649 on KOSDAQ (top 48%), #155 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 78.99B KRW | KR#1,395/2,436 Sec#155/234 |
| Revenue | 70.93B KRW | KR#1,601/2,436 Sec#104/234 |
| Net Income | 8.89B KRW | KR#939/2,436 Sec#61/234 |
| Total Assets | 247.04B KRW | KR#1,130/2,436 Sec#78/234 |
| Net Assets | 228.11B KRW | KR#857/2,436 Sec#59/234 |
| Employees | 316 | KR#755/2,436 Sec#66/234 |
| Value | ||
| P/E | 8.89x | KR#627/2,436 Sec#29/234 |
| P/B | 0.35x | KR#429/2,436 Sec#15/234 |
| P/S | 1.11x | KR#1,469/2,436 Sec#85/234 |
| EV/EBITDA | 11.64x | KR#697/2,436 Sec#35/234 |
| FCF Yield | 11.84% | KR#558/2,436 Sec#19/234 |
| Profitability | ||
| ROE | 3.90% | KR#1,126/2,436 Sec#82/234 |
| ROA | 3.60% | KR#855/2,436 Sec#75/234 |
| Op. Margin | 7.93% | KR#636/2,436 Sec#57/234 |
| Revenue Growth | -28.05% | KR#2,152/2,436 Sec#195/234 |
| Earnings Growth | -64.51% | KR#1,263/2,436 Sec#82/234 |
| Financial Health | ||
| Debt Ratio | 8.30% | KR#7/2,436 Sec#1/234 |
| Total Debt | 1.14B KRW | KR#1,948/2,436 Sec#189/234 |
| FCF | 9.35B KRW | KR#722/2,436 Sec#40/234 |
| Cash | 14.67B KRW | KR#1,427/2,436 Sec#107/234 |
| Current Ratio | 7.79x | KR#160/2,436 Sec#38/234 |
| Net Debt/EBITDA | -2.41x | KR#261/2,436 Sec#14/234 |
| Dividend | ||
| Div. Yield | 6.97% | KR#114/2,436 Sec#3/234 |
| Div. Growth | 6.25% | KR#634/2,436 Sec#34/234 |
| Performance | ||
| 1Y Return | -30.42% | KR#1,579/2,436 Sec#136/234 |
| 1M Return | -3.88% | KR#1,291/2,436 Sec#131/234 |
| From 52W High | -33.40% | KR#515/2,436 Sec#33/234 |
| 1Y MDD | -35.75% | KR#370/2,436 Sec#26/234 |
| Trading | ||
| Volume | 4,227 shares | KR#2,286/2,436 Sec#225/234 |
| Foreign Own. | 1.43% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,395 KRW | KR#498/2,436 Sec#35/234 |
| BPS | 37,011 KRW | KR#308/2,436 Sec#20/234 |
Company Info
Sama Pharmaceutical, founded as Bogun Pharmaceutical Laboratory in 1945 and incorporated in 1973, was listed on KOSDAQ in 2000. It manufactures and sells a wide range of pharmaceuticals, including respiratory, antibiotic, dermatological, and digestive system drugs, with key products like Citoos, Codenal, Hebron, and Setofen. The company completed its Munmak factory as a KGMP pharmaceutical production facility in 2009 and continues to develop differentiated generic products through new drug and new product research and development. Sama Pharmaceutical is headquartered in Wonju-si, Gangwon-do.